Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours by Lankheet, N. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/136010
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Pharmacokinetically guided sunitinib dosing:
a feasibility study in patients with advanced
solid tumours
N A G Lankheet1,6, J S L Kloth2,6, C G M Gadellaa-van Hooijdonk3,4,6, G A Cirkel3,4, R H J Mathijssen2,4,
M P J K Lolkema3,4, J H M Schellens4,5, E E Voest3,4, S Sleijfer2,4, M J A de Jonge2,4, J B A G Haanen5,
J H Beijnen1, A D R Huitema1 and N Steeghs*,4,5
1Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 2Department
of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands; 3Department of
Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; 4Center for
Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands and 5Department of Medical Oncology
and Clinical Pharmacology, The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam,
The Netherlands
Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was
performed to determine safety and feasibility of sunitinib dosing based on PK levels.
Methods: Patients were treated with sunitinib 37.5mg once daily. At days 15 and 29 of treatment, plasma trough levels of sunitinib
and N-desethyl sunitinib were measured. If the total trough level (TTL) waso50 ngml 1 and the patient did not show any grade
X3 toxicity, the daily sunitinib dose was increased by 12.5mg. If the patient suffered from grade X3 toxicity, the sunitinib dose
was lowered by 12.5mg.
Results: Twenty-nine out of 43 patients were evaluable for PK assessments. GradeX3 adverse events were experienced in seven
patients (24%) at the starting dose and in nine patients (31%) after dose escalation. TTLs were below target in 15 patients (52%) at
the starting dose. Of these, five patients (17%) reached target TTL after dose escalation without additional toxicity.
Conclusions: In a third of the patients that were below target TTL at standard dose, the sunitinib dose could be increased without
additional toxicities. This could be the basis for future studies and the implementation of a PK-guided dosing strategy in clinical
practice.
Sunitinib (Sutent) has proven its efficacy as single agent in several
solid tumour types and is approved for use in advanced renal cell
cancer (RCC), imatinib-resistant or -intolerant gastrointestinal
stromal tumours (GISTs) and pancreatic neuroendocrine tumours
(pNET) (Demetri et al, 2006; Motzer et al, 2006; Raymond et al,
2011). Recent findings demonstrated a positive dose-efficacy
relationship for sunitinib treatment (Houk et al, 2010). As deduced
from pharmacokinetic/pharmacodynamic preclinical data, target
total plasma concentrations of sunitinib plus active metabolite
(N-desethyl sunitinib) are in the range of 50–100 ngml 1 (Abrams
et al, 2003a, b; Mendel et al, 2003; Murray et al, 2003; Faivre et al,
2006). In line with these preclinical data, total trough levels (TTLs)
o50 ngml 1 have been associated with decreased therapeutic
efficacy in patients compared with patients with TTL above this
level (Faivre et al, 2006). It is therefore hypothesised that for
optimal sunitinib therapy a TTL of 450 ngml 1 should be
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reached in each individual patient. However, sunitinib exposure
shows considerable variation due to patient non-compliance (e.g.,
due to drug-related toxicity), drug interactions with co-medication,
variability in oral drug availability and many other factors
(Klumpen et al, 2011). Despite this considerable inter-patient
variability in systemic exposure, sunitinib is currently prescribed at
a fixed dose. Given the narrow therapeutic index, the large inter-
individual variability in systemic exposure, and the positive
exposure–efficacy relationship, there is a strong rationale for
pharmacokinetically (PK) guided dosing also known as therapeutic
drug monitoring (TDM) of sunitinib (de Jonge et al, 2005; Faivre
et al, 2006; Houk et al, 2010). Such an approach could contribute to
a tailor-made sunitinib treatment with improved therapeutic
efficacy and decreased risk for toxicity (Beumer, 2013).
Thus far, no prospective clinical trials investigating the
safety and efficacy of PK-guided dosing for sunitinib therapy
have been performed. Hence, the ultimate proof that reaching
target trough concentrations increases treatment efficacy remains
to be awaited. As a first step towards individualised PK-based
dosing, we investigated the safety and feasibility of PK-guided
sunitinib dosing in a pilot study by measuring sunitinib trough
levels. The main purpose of the study was to assess whether
PK-guided dosing could be performed without causing additional
toxicities. Establishing a feasible and safe PK-guided dosing
strategy could provide a rationale for a large prospective clinical
trial.
MATERIALS AND METHODS
Patient population. This multicenter prospective pilot trial
(NCT01286896) was initiated in 2011 and was performed in three
medical centres in the Netherlands. Eligible patients were patients
with histologically or cytologically confirmed advanced tumours
for which sunitinib was considered standard therapy or patients
with advanced or metastatic tumours for whom no standard
therapy was available.
Other inclusion criteria included age X18 years; an Eastern
Cooperative Oncology Group performance status p1; measurable
or evaluable disease according to Response Evaluation Criteria
Solid Tumours 1.1 criteria; estimated life expectancy 412 weeks;
adequate haematologic, hepatic and renal function; no cardiac
instability within the previous 6 months. Additionally, patients
should be able and willing to undergo blood sampling, and patients
should be able to swallow oral medication.
The protocol was approved by local independent ethics
committees, and the study was conducted in accordance with the
Declaration of Helsinki. All patients received information regard-
ing the purpose and conduct of this study and provided written
informed consent.
Study design. Eligible patients started treatment at a dose level of
37.5mg sunitinib once daily continuously. At day 15 of sunitinib
treatment, TTLs of sunitinib plus N-desethyl sunitinib were
measured. If the TTL was o50 ngml 1 and the patient did not
experience any grade X3 toxicity (CTCAE 4.02), the daily
sunitinib dose was increased by 12.5mg at day 22. At day 29,
7 days after the first dose adjustment, the second TTL was
measured. If indicated, a second dose adjustment based on TTL
and/or toxicity was performed at day 36, as described before. After
8 weeks a final TTL evaluation was performed. No further dose
increments were allowed.
If the patient suffered from grade X3 toxicity or intolerable
grade 2 toxicity despite supportive care at any moment during the
study, the sunitinib treatment was interrupted until adequate
recovery (CTC grade o2) was achieved. Subsequently, sunitinib
treatment was resumed at the next lowest dose level. Sunitinib dose
levels allowed within this study were 12.5, 25, 37.5, 50 and 62.5mg
QD. Patients experiencing grade 42 toxicity with sunitinib
12.5mg once daily discontinued the treatment and went off-study.
No dose escalations were allowed after a previous dose reduction
for toxicity. Treatment was continued until progressive disease,
until patient refusal or until adverse events that required
discontinuation of therapy were observed.
Pharmacokinetic analyses. Samples for pharmacokinetics (PK)
were collected at day 15±1, day 29±1 and after 8 weeks (day
57±1) of sunitinib treatment. EDTA blood samples were collected
and, thereafter, directly sent to the laboratory by ordinary mail at
ambient temperature. After receipt of the samples, within 36 h after
blood collection, plasma was harvested and stored at  20 1C until
analysis.
Trough levels of sunitinib and N-desethyl sunitinibin plasma
were measured by LC-MS/MS as described before (Lankheet et al,
2013). Total trough levels were determined by calculating the sum
of sunitinib and N-desethyl sunitinib plasma levels and were
reported to the treating physician within 1 week after blood
collection. Patients were evaluable for pharmacokinetic analyses if
they had undergone all three PK blood samplings.
Safety assessments. Adverse events (AE), serious adverse events
(SAE) and their relationship with study medication were assessed
throughout the study. The incidence and severity of AEs were
evaluated and graded using the National Cancer Institute Common
Toxicity Criteria for Adverse Events version 4.02 (CTCAE 4.02).
Patients who received at least one dose of the study treatment were
included in the safety evaluation.
Statistical analysis. The number of patients recruited was based
on the number estimated to be required to evaluate at least eight
patients for toxicity after PK-guided dose escalation. It was
expected that 45% of patients would experience clinically relevant
toxicity at the starting dose of 37.5mg once daily (van der Veldt
et al, 2008; Escudier et al, 2009; George et al, 2009; Novello et al,
2009; van Erp et al, 2009). In addition, it was expected thatB50%
of the patients without toxicity (55%) would have TTL
X50 ngml 1 (George et al, 2009; Novello et al, 2009). In both
occasions, patients were not eligible for dose escalation. Thus, to be
able to evaluate at least eight patients after dose escalation, it was
necessary to include about four times as many patients (at least 30
patients).
Descriptive statistics were used to summarise the patient
characteristics, toxicity data, response data and sunitinib TTLs.
RESULTS
Patient population. From April 2011 until June 2012, 43 patients
with a variety of advanced solid tumours were enrolled (18 patients
at the Netherlands Cancer Institute–Antoni van Leeuwenhoek
Amsterdam, 15 patients at the University Medical Center Utrecht
and 10 patients at the Erasmus MC Cancer Institute Rotterdam).
Forty-two patients received at least one dose of sunitinib and were
evaluable for toxicity assessments. Twenty-nine patients completed
all three pharmacokinetic blood samples and were therefore
evaluable for pharmacokinetic assessments (see Figure 1 for
CONSORT diagram). In total, 14 out of 29 patients were evaluable
for toxicity assessment after PK-guided dose escalation. At the time
of the database lock (August 2012), four patients (9.5%) were still
on sunitinib therapy. Demographical and clinical characteristics for
all patients are provided in Table 1.
Target trough levels. After 14 days of sunitinib treatment, the
median TTL was 49.5 ngml 1 (IQR 41.8–64.0) (see Table 2).
Considerable inter-patient variability of TTLs was observed at the
starting dose with a coefficient of variation (CV%) of 32.1%.
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Moreover, 15 out of 29 patients (52%) did not reach the target TTL
of 50 ngml 1 at the starting dose of 37.5mg per day. Therefore,
dose escalations to 50mg per day were indicated in 15 patients.
However, in one patient it was not possible to increase the
sunitinib dose due to haematological toxicity, and therefore dose
escalation was performed in 14 patients. At the second PK
evaluation (day 29), the median TTL was increased to 57.6 ngml 1
(IQR 48.3–61.9) with an inter-patient variability of 35.2% for the
entire population of 29 patients. The 14 patients that had
undergone dose escalation after day-15 PK measurement (median
TTL 42.0 ngml 1 (IQR 36.3–47.3)) reached median TTL of
51.3 ngml 1 (IQR 44.7–58.7) at day 29. In two patients dose
escalation at day 15 resulted in reduced TTL at day 29. Moreover,
19 out of 29 patients (66%) reached the target TTL. Of the 10
patients below the target level, the sunitinib dose was increased to
62.5mg per day in 3 patients and dose escalations were not
possible due to toxicity in 7 patients. At the final PK evaluation
(day 57), the median TTL was reduced to 51.8 ngml 1 (40.3–63.7)
with an inter-patient variability of 45% and 15 patients (52%)
reached the target TTL. Six patients in Group 2 showed a decrease
in TTL throughout the study without dose adjustments. In two
cases this resulted in TTL below the target TTL at day 57. In
Figure 2, the measured TTLs of individual patients at days 15, 29
and 57 are presented.
PK-guided dosing. Based on TTL reached at day 15, two patient
groups were distinguished: Group 1, which consisted of patients
who did not reach target TTL and Group 2, which consisted of
patients who reached target TTL. Based on toxicity in the first 8
weeks of treatment, these groups could be subdivided further into
four patient subgroups with different results of the PK guided
dosing strategy. The defined groups were as follows: Group 1a
patients with TTLo50 ngml 1 at day 15 and no relevant toxicity
(n¼ 5; 17%), Group 1b patients with TTLo50 ngml 1 at day 15
with relevant toxicity (n¼ 10; 34%), Group 2a patients with
TTL450 ngml 1 at day 15 and no relevant toxicity (n¼ 8; 28%),
Group 2b patients with TTL450 ngml 1 at day 15 with relevant
toxicity (n¼ 6; 21%). As shown in Table 2, the five patients (17%)
who did not reach target TTL at day 15 and had PK-guided dose
elevations without relevant toxicity tolerated treatment with 47%
higher mean daily dose compared with standard therapy. After
8 weeks of treatment the distribution of daily sunitinib doses in
the study population was as follows: 2 patients using 62.5mg,
4 patients using 50mg, 15 patients using 37.5mg and 8 patients
using 25mg. Presumably without PK-guided dosing the result
would have been 21 patients on 37.5mg, 8 on 25mg, and therefore
a possible underdosing in 6 of 29 (21%) of patients.
In Figure 3, an overview of all dose adjustments and TTLs is
shown per individual patient within the 8-week study period.
Treatment toxicity. The most frequently occurring treatment
related adverse events are listed in Table 3. Grade X3 adverse
events were observed in 29 patients (69%). The main grade X3
adverse events attributed to study treatment included hypertension
(14%), fatigue (12%), anaemia (12%), thrombocytopenia (12%) and
hand-foot syndrome (HFS) (10%). Common grade 1 or 2 non-
haematologic treatment-related toxicities were fatigue (60%),
nausea (50%), dysgeusia (55%), oral mucositis (52%), diarrhoea
(40%), HFS (33%) and vomiting (29%).
Six patients discontinued sunitinib treatment (at the standard
dose of 37.5mg per day) due to adverse events before the final PK
evaluation at day 57; five of these discontinuations were considered
treatment-related and included fatal cardiac failure (n¼ 1, grade
5), fatigue, increased blood bilirubin, nausea (all n¼ 1, grade 3)
and fatigue (n¼ 1, grade 2). Dose reductions of sunitinib due to
treatment-related adverse events during the PK evaluation period
were performed in 16 patients (Group 1bþ 2b). Moreover, nine of
these patients (56%) (Group 1b) who had an initial TTL-guided
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Figure 1. Patient flow diagram.
Table 1. Baseline characteristics of all evaluable patients
Characteristic Patients (n¼42)
Gender (number (%))
Male 28 (67)
Female 14 (33)
Age (y) (median (range)) 61 (28–74)
Bodyweight (kg) (median (range)) 77 (44–108)
Ethnicity (number (%))
Caucasian 42 (100)
ECOG performance status (number (%))
0 10 (24)
1 32 (76)
Primary tumour (number (%))
Neuroendocrine carcinoma 8 (19)
Colorectal carcinoma 8 (19)
Renal cell carcinoma 6 (14)
Adenocarcinoma of unknown primary (ACUP) 3 (7)
Uveal melanoma 3 (7)
Miscellaneousa 14 (33)
Clinical stage, pretreatment (number (%))
Locally advanced 2 (5)
Metastatic 40 (95)
Prior treatment (number (%))
TKI therapy 5 (36)
Chemotherapy 31 (74)
1 regimen 12 (29)
2 regimens 3 (7)
X3 regimens 17 (40)
Surgery 28 (67)
Radiotherapy 16 (38)
aMiscellaneous: pancreatic carcinoma (n¼ 2), hepatocellular carcinoma (n¼ 2), oesopha-
geal carcinoma (n¼ 2), prostate carcinoma, cervix carcinoma, head and neck carcinoma,
mesothelioma, liposarcoma, ewing sarcoma, myo-epithelioma, osteosarcoma.
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dose increase did not tolerate this higher dose level, as shown in
Figure 3. In addition, five patients discontinued sunitinib treatment
due to toxicity after the PK evaluation period; two of these
discontinuations were considered treatment related and included a
combination of anaemia and thrombocytopenia (n¼ 2, grade 3).
The main purpose of the study was to assess whether PK-guided
dosing could be performed without causing additional toxicities.
Therefore, the occurrence of toxicities in the patients who required
dose escalations (Group 1) was compared with patients who did
not need dose interventions based on PK and remained at the
standard dose (Group 2). In all patient groups, the frequency of
gradep2 toxicity was similar. TTLs above the target level at day 15
of therapy did not correlate to frequency of severe toxicity
(grade X3). In Group 1, 10 out of 15 patients (67%) experienced
severe toxicities and in Group 2 with TTL 450 ngml 1, 6 out of
14 patients (43%) experienced severe toxicity.
DISCUSSION
In this pilot study, the safety and feasibility of PK-guided sunitinib
dosing was investigated. At the standard dose of 37.5mg, 52% of
patients did not reach target TTLs of sunitinib after 14 days of
Table 2. Therapy outcomes regarding reached total trough level (TTL), dose and target TTL, stratified by patient group
Outcome
Group 1a
TTLo50
No severe TOX
(n¼5)
Group 1b
TTLo50
Severe TOX
(n¼10)
Group 2a
TTLX50
No severe TOX
(n¼8)
Group 2b
TTLX50
Severe TOX
(n¼6)
Total
(n¼29)
TTL (ngml1) (median (IQR))
Day 15 44.0 (41.8–48.8) 39.1 (30.1–43.0) 65.5 (56.8–67.9) 62.2 (56.0–64.7) 49.5 (41.8–64.0)
Day 29 51.8 (45.6–61.5) 50.2 (43.3–56.3) 61.4 (58.7–79.3) 53.1 (40.1–65.8) 57.6 (48.3–61.9)
Day 57 63.9 (56.2–78.3) 39.6 (31.1–48.2) 61.9 (55.0–69.6) 46.4 (37.5–53.6) 51.8 (40.3–63.7)
Dose (mg) (mean (s.d.))
Day 29 50.0 ( ) 47.5 (7.9) 37.5 ( ) 33.3 (6.5) 42.7 (7.8)
Day 57 55.0 (6.8) 35.0 (5.3) 37.5 ( ) 25.0 ( ) 37.9 (9.7)
Patients on target TTL (number (%))
Day 15 0 (0) 0 (0) 8 (100) 6 (100) 14 (48)
Day 29 3 (60) 5 (50) 8 (100) 3 (50) 19 (66)
Day 57 5 (100) 1 (10) 6 (75) 3 (50) 15 (52)
Abbreviations: IQR¼ interquartile range; s.d.¼ standard deviation; TOX¼ toxicity; TTL¼ total trough level. Patients were stratified by TTL measured at day 15 and toxicity within 8 weeks of
treatment. Patients with TTLo50 ngml 1 at day 15 are in group 1. Patients with TTLX50 ngml 1 are in group 2. In addition, subgroups are formed by patients without severe toxicity within 8
weeks of treatment (Groups 1a and 2a) and patients suffering from severe toxicity within 8 weeks (Groups 1b and 2b).
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Figure 2. Total trough levels measured at days 15, 29 and 57 of sunitinib treatment of all patients who were evaluable for PK evaluation,
stratified by patient group. The black bars represent the median TTL.
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Figure 3. Course of sunitinib dose levels and TTLs during the first 8 weeks of treatment of all individual patients who were evaluable for PK
evaluation, stratified by patient group.On the x axis is the week number, on the y axis both sunitinib dose level and TTLs are presented. Red dots
represent TTLs. Black squares represent dose levels. The dotted line represents the target TTL (50 ngml 1). Group 1a: patients with TTL
o50ngml 1 at day 15 and without toxicity; Group 1b: patients with TTL o50 ngml 1 at day 15 and with toxicity; Group 2a: patients with TTL
450ngml 1 at day 15 and without toxicity; Group 2b: patients with TTL 450ngml1 at day 15 and with toxicity.
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Table 3. Toxicity data
Gradep2 GradeX3 Any
grade
Discontinued Group 1 Group 2 Total Discontinued Group 1 Group 2 Total Total
(n¼13)
Group 1a
(n¼5)
Group 1b
(n¼10)
Group 2a
n¼ (8)
Group 2b
n¼ (6) (n¼42) (n¼13)
Group 1a
(n¼5)
Group 1b
(n¼10)
Group 2a
(n¼8)
Group 2b
(n¼6) (n¼42) (n¼42)
Adverse
event n % n % n % n % n % n % n % n % n % n % n % n % n %
Treatment-related non-haematological adverse events (ocurring in X10% of patients)
Fatigue 7 54 4 80 6 60 5 63 3 50 25 60 2 15 0 0 2 20 0 0 1 17 5 12 30 71
Nausea 6 46 3 60 4 40 4 50 4 67 21 50 2 15 0 0 0 0 1 13 0 0 3 7 24 57
Dysgeusia 6 46 4 80 5 50 4 50 4 67 23 55 0 0 0 0 0 0 0 0 0 0 0 0 23 55
Oral mucositis 3 23 2 40 8 80 5 63 4 67 22 52 0 0 0 0 0 0 0 0 1 17 1 2 23 55
Diarrhoea 3 23 3 60 3 30 4 50 4 67 17 40 0 0 1 20 1 10 1 13 0 0 3 7 20 48
Hand-foot
syndrome
2 15 3 60 5 50 2 25 2 33 14 33 0 0 0 0 3 30 1 13 0 0 4 10 18 43
Vomiting 4 31 5 100 2 20 1 13 0 0 12 29 0 0 0 0 0 0 1 13 0 0 1 2 13 31
Hypertension 1 8 1 20 0 0 3 38 0 0 5 12 2 15 2 40 0 0 1 13 1 17 6 14 11 26
Anorexia 2 15 0 0 2 20 0 0 2 33 6 14 1 8 0 0 0 0 0 0 0 0 1 2 7 17
Dry skin 2 15 2 40 2 20 0 0 2 33 8 19 0 0 0 0 0 0 0 0 0 0 0 0 8 19
Rash 0 0 0 0 3 30 4 50 1 17 8 19 0 0 0 0 0 0 0 0 0 0 0 0 8 19
Constipation 1 8 1 20 3 30 1 13 0 0 6 14 1 8 0 0 0 0 0 0 0 0 1 2 7 17
Epistaxis 2 15 0 0 2 20 2 25 0 0 6 14 0 0 0 0 0 0 0 0 1 17 1 2 7 17
Dyspnoea 2 15 0 0 2 20 1 13 0 0 5 12 1 8 0 0 0 0 0 0 0 0 1 2 6 14
Skin yellow
discoloration
2 15 0 0 1 10 2 25 1 17 6 14 0 0 0 0 0 0 0 0 0 0 0 0 6 14
Dyspepsia 0 0 2 40 1 10 1 13 1 17 5 12 0 0 0 0 0 0 0 0 0 0 0 0 5 12
Hair
depigmentation
0 0 2 40 1 10 2 25 0 0 5 12 0 0 0 0 0 0 0 0 0 0 0 0 5 12
Oral pain 1 8 0 0 0 0 4 50 0 0 5 12 0 0 0 0 0 0 0 0 0 0 0 0 5 12
Periorbital
oedema
2 15 0 0 2 20 0 0 1 17 5 12 0 0 0 0 0 0 0 0 0 0 0 0 5 12
Periph.
Neuropathy
1 8 0 0 2 20 1 13 1 17 5 12 0 0 0 0 0 0 0 0 0 0 0 0 5 12
Laboratory abnormalities
Haematology
Anaemia 1 8 0 0 0 0 0 0 0 0 1 2 1 8 0 0 1 10 1 13 2 33 5 12 6 14
White blood
cells
0 0 0 0 0 0 1 13 1 17 2 2 0 0 0 0 1 10 0 0 1 17 2 5 4 10
Neutrophils 0 0 1 20 2 20 0 0 3 50 6 14 1 8 1 20 2 20 0 0 1 17 5 12 11 26
Platelets 1 8 1 20 0 0 2 25 0 0 4 10 0 0 0 0 1 10 0 0 2 33 3 7 7 17
Clinical chemistry
ALAT 0 0 0 0 1 10 2 25 0 0 3 7 0 0 1 20 0 0 1 13 0 0 2 5 5 12
ASAT 0 0 0 0 0 0 1 13 0 0 1 2 0 0 1 20 1 10 1 13 0 0 3 7 4 10
Creatinine
increased
0 0 0 0 1 10 1 13 1 17 3 7 1 8 0 0 0 0 0 0 0 0 1 2 4 10
Cardial events
Heart failure 0 0 0 0 0 0 0 0 0 0 0 0 1 8 1 20 0 0 0 0 0 0 2 5 2 5
Acute
coronairy
syndrome
0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 0 0 0 0 0 0 0 1 2 1 2
Prolonged
QT interval
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 13 0 0 1 2 1 2
Myocardial
infarction
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 13 0 0 1 2 1 2
Any toxicity 13 100 5 100 10 100 8 100 6 100 100 7 54 3 60 9 90 5 63 5 83 29 69 100
Abbreviations: ALAT¼ alanine aminotransferase; ASAT¼ aspartate aminotransferase. Group 1a: patients with TTLo50 ngml 1 at day 15 and without toxicity; Group 1b: patients with TTL
o50 ngml 1 at day 15 and with toxicity; Group 2a: patients with TTL 450 ngml 1 at day 15 and without toxicity; Group 2b: patients with TTL 450 ngml 1 at day 15 and with toxicity.
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sunitinib treatment. Ultimately, 5 out of 29 patients (17%) had
successful dose escalations with final doses of 50mg (n¼ 3) and
62.5mg (n¼ 2), leading to TTLs above the target without causing
additional toxicities. This implies that PK-guided sunitinib dose
escalations rather than fixed doses can contribute to optimisation
of therapy in a part of the patients.
Similar to classical anticancer chemotherapy regimens, it is
often reasoned that increasing the dose of an anticancer drug in
patients who lack toxicity might increase the likelihood of
treatment efficacy (Mita et al, 2011; Gao et al, 2012; Pond et al,
2012; Rini et al, 2013). Fixed dosing may lead to underdosing due
to inadequate drug exposure in some patients. Dosing to toxicity
might lead to overdosing and unnecessary side effects, as in some
patients adequate drug exposure will already be accomplished with
a lower dose. This is complex since drug exposure, toxicity and
efficacy generally do not show a linear relationship and it is not
known whether toxicity is accompanied by adequate exposure.
Therefore, therapeutic drug monitoring for the individualisation of
dosing of anticancer drugs with a considerable and unpredictable
inter-patient variability in pharmacokinetics is gaining popularity.
For example, PK-guided dosing has been mentioned for docetaxel
leading to a decrease in the inter-patient variability of drug
exposure (Engels et al, 2011). However, to our knowledge, the
current study is the first in which PK-guided dosing is applied to
sunitinib treatment.
The sunitinib starting dose of 37.5mg (continuously once-daily)
was based on previously reported studies investigating a contin-
uous dosing strategy for sunitinib (Escudier et al, 2009; George
et al, 2009; Novello et al, 2009). As no safety data were available
regarding long-term continuous daily dosing of high-dose
sunitinib, the highest dose level was maximised to 62.5mg per
day (Escudier et al, 2009; George et al, 2009; Novello et al, 2009;
Motzer et al, 2012).
A limitation of this study is that target TTL have not been
established in clinical studies, thus far. The association between
sunitinib exposure and efficacy was based on the steady-state area
under the concentration–time curve (AUC) (Houk et al, 2010). As
both AUC and trough level increase proportionally with dose,
these parameters should correlate with each other (EMA, 2007;
Faivre et al, 2006). Hence, the target plasma levels used in this
study were deduced from preclinical studies (Abrams et al,
2003a, b; Mendel et al, 2003; Murray et al, 2003). Furthermore,
our study was performed in a small cohort of patients with a large
variety of advanced solid tumours and without a control group.
Therefore, it was not possible to investigate the relationship
between plasma exposure and treatment efficacy.
In the previously reported studies, mean TTLs were
B40–65 ngml 1 and inter-patient variability was high with a
coefficient of variation (CV) of430% (Escudier et al, 2009; George
et al, 2009; Novello et al, 2009; Motzer et al, 2012). Our patient
cohort showed comparable results after 14 days of treatment
(before any dose change) with median TTL of 49.5 ngml 1 and an
inter-patient variability of 31.2%. When assuming that target TTLs
are needed for adequate treatment responses, this means that more
than half of the patients were at subtarget levels (o50 ngml 1) at
the standard dose.
Based on the elimination half-life of sunitinib (±40 h) and
N-desethyl sunitinib (±80 h) it was expected that steady-state
concentrations would be reached within 14 days of treatment and
that parent and metabolite accumulate 3–4-fold and 7–10-fold,
respectively (EMA, 2007). However, no significant drug accumula-
tion was observed after 3 weeks of continuous sunitinib treatment
in previous studies (George et al, 2009; Barrios et al, 2012).
Additionally, in case of a dose escalation from 37.5mg to 50mg
(33% increment) 490% of the new steady-state level would
already be reached after two half-lifes since the new steady state is
close to the former level. Therefore, TTL measurement 7 days after
a dose escalation was expected to be adequate. However, in some
patients TTLs still tended to increase after 2 weeks of sunitinib
treatment even when the dose remained equal. A longer period
before collection of the first TTL sample was considered, but this
would postpone potential beneficial dose increments. In addition,
it was observed that TTLs in two out of eight patients decreased to
below the target TTL without a dose reduction after 8 weeks of
treatment. It is not known whether this is due to unexplained
intra-patient variability, patient non-adherence (despite using
diaries and pill counts) or whether sunitinib levels tend to decrease
after long term treatment as was shown for imatinib (Eechoute
et al, 2012) and sorafenib (Arrondeau et al, 2012; Boudou-
Rouquette et al, 2012). Hence, further insights in TTLs and inter-
patient pharmacokinetic variability during sunitinib treatment are
warranted to allow rational design of future PK-guided dosing
studies (Kloth et al, 2013).
The total occurrence of toxicity grade 3 or higher observed in
this study was consistent with previously reported studies on
continuous daily dosing regimens of sunitinib (Escudier et al, 2009;
George et al, 2009; Novello et al, 2009; Motzer et al, 2012). Owing
to the small patient number this study was not powered to
compare the occurrence of toxicities within the different patient
subgroups.
Of all 16 patients who required dose reductions due to toxicity
(Group 1bþ 2b), 7 patients suffered from toxicities at the standard
dose and would also have experienced these toxicities if they were
treated without the PK-guided dosing strategy. The same goes for
one patient in the study who died due to a probable treatment-
related adverse event (diffuse cardiac ischaemia followed by cardiac
failure) at the starting dose of 37.5mg per day. However, as could
be expected, patients did experience additional toxicities after PK-
guided dose escalations (nine patients). These toxicities were
manageable by dose reductions.
As suggested by previous data, it was expected that toxicity was
correlated to sunitinib exposure (Houk et al, 2010). However,
results indicated that the frequency of severe toxicities (grade X3)
was not correlated to TTL at day 15, as toxicity levels at that time-
point were comparable in the patients with TTL o50 ngml 1
(Group 1) and TTL 450 ngml 1 (Group 2). Probably toxicity is
alsocorrelated to cumulative sunitinib exposure instead of the
initial steady state TTL, as was also reported for absolute
neutrophil counts by Houk et al (2010).
In addition, the daily sunitinib doses after 8 weeks of treatment
in our patient cohort also give insights in a possible added value of
a PK-guided dosing strategy. Six patients (21%) were treated with
sunitinib doses above the standard dose of 37.5mg per day. These
patients would probably be underdosed in a fixed dosing regimen.
There are several benefits of a PK-guided dosing approach for
sunitinib. First, one could hypothesise, based on our results and
previous work by other groups, that if an effective TTL can not be
reached at a dose level with tolerable toxicity in these patients, TTL
assessments could substantiate the choice to switch to another
more effective therapy. Second, when assuming that TTLs
450 ngml 1 are needed for adequate treatment responses, 17%
of patients (the five patients in Group 1a (TTLo50 ngml 1 and
no toxicity)) benefit from PK-guided dose increases without
additional toxicity. Third, compared with a toxicity-based
approach, additional toxicities might be avoided, because adequate
drug exposure is reached before toxicity occurs. However, efficacy
of both approaches have not been studied or compared in great
detail sofar.
In the current oncology field we are more and more searching
for personalised treatments options for a sometimes small number
of patients. With a little effort we can sometimes optimise the
treatment options we already have. Individualising dosing of
sunitinib based on a simple measurement of plasma concentration
is worthwhile to investigate further in order to utilise the scarce
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treatment options available for many tumour types in a most
optimal way. Further research is therefore required to investigate
the safety and therapeutic efficacy of PK-guided dosing of sunitinib
in order to reach a systemic exposure above the target TTL
compared with that from a standard fixed dose.
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